"Newly unveiled court documents show that ghostwriters paid by a pharmaceutical company played a major role in producing 26 scientific papers backing the use of hormone replacement therapy in women," reports Natasha Singer. "The articles, published in medical journals between 1998 and 2005, emphasized the benefits and de-emphasized the risks" of Premarin and Prempro, two homone drugs produced by the Wyeth pharmaceutical company.
The healthcare industry is waging a "record-breaking influence campaign," spending "more than $1.4 million a day on lobbying," reports the Washington Post. "The Pharmaceutical Research and Manufacturers of America (PhRMA) doubled its spending to nearly $7 million in the first quarter of 2009, followed by Pfizer, with more than $6 million" spent in just three months.
The global drug firm Roche has decided to withdraw from the Pharmaceutical Research and Manufacturers Association (PhRMA), the peak lobbying group for the U.S. drug industry.
"Prescription drug ads have drawn fire for portraying healthy-looking, active and smiling patients while explaining benefits and then rushing through or providing distractions when required risk information is presented," reports Reuters.
The Wall Street Journal has published a revealing story about one of the seamier sides of the drug industry's marketing campaigns: paying patients to offer testimonials about their drugs. As health industry observer Merrill Goozner explains, the story came to light because a "celebrity patient" had a "falling out with his corporate sponsor, Bristol-Myers Squibb.
The pharmaceutical company Merck "paid an undisclosed sum to Elsevier to produce several volumes of a publication that had the look of a peer-reviewed medical journal, but contained only reprinted or summarized articles -- most of which presented data favorable to Merck products." The Australasian Journal of Bone and Joint Medicine carried "ads for Fosamax, a Merck drug for osteoporosis, and Vioxx" and "appeared to act solely as market